Core Insights - Prenetics Global Limited will participate in the 38th Annual ROTH Conference from March 22nd to March 24th, 2026 [1] - CEO Danny Yeung and President of Americas David Vanderveen will hold one-on-one meetings and participate in a fireside chat and a Consumer Influencer panel discussion during the conference [2] - IM8, Prenetics' flagship brand, has surpassed $100 million in annualized recurring revenue within 11 months of operations and is sold in over 30 countries [4] Company Overview - Prenetics is a leading health sciences company focused on advancing human health and longevity, with its premium brand IM8 co-founded by David Beckham [4] - IM8 combines cutting-edge science with natural ingredients to provide a holistic approach to health, featuring its flagship product, Daily Ultimate Essentials, which replaces 16 different supplements [5] - IM8 is NSF Certified for Sport, non-GMO, vegan, and free from common allergens, artificial flavors, colors, or sweeteners [5]

Company Overview - Kenvue Inc. is a global consumer health company headquartered in Summit, New Jersey, with a market cap of approximately $34.8 billion, categorizing it as a large-cap company [1] - The company focuses on everyday health and personal care products, maintaining a diverse portfolio that addresses a wide range of daily health needs [1] Product Portfolio - Kenvue offers over-the-counter treatments for various health issues, including cough, cold, allergies, pain relief, and digestive health, alongside skincare, haircare, oral care, and baby care products [2] - The company features well-known brands such as Tylenol, Benadryl, Zyrtec, Neutrogena, Aveeno, Listerine, BAND-AID, and Johnson's, which have built consumer trust over decades [2] Stock Performance - Kenvue's stock is currently trading 28.7% below its 52-week high of $25.17 reached in May 2025, with a modest increase of 3.7% over the past three months [3] - Over the last 52 weeks, Kenvue's shares have declined by 24.9%, although there has been a 4.1% gain year-to-date (YTD) [6] - In comparison, the State Street Consumer Staples Select Sector SPDR ETF (XLP) has increased by 3.7% over the same 52-week period and surged by 10.4% in 2026 [6] Technical Indicators - Since mid-November 2025, Kenvue's shares have mostly traded above their 50-day moving average of $17.85, indicating short-term stability [7] - However, the stock has consistently remained below its 200-day moving average of $18.75 since August 2025, suggesting a lack of investor confidence in the stock's long-term trajectory [7] Financial Performance - In the latest earnings release on February 17, 2025, Kenvue reported Q4 revenue of $3.78 billion, reflecting a year-over-year increase of 3.2% and surpassing Street expectations of $3.71 billion [8]

Core Viewpoint - Prenetics Global Limited has announced a share repurchase program of up to $40 million, reflecting the Board's belief that the current share price does not accurately represent the company's underlying value and growth trajectory [1][5][10] Financial Performance and Capital Allocation - The executive leadership team of Prenetics has invested approximately $2.75 million of personal capital into the company's stock over two recent post-earnings trading windows, indicating strong internal confidence in the company's prospects [2][3][4] - Prenetics has approximately $164 million in total adjusted liquidity and zero debt as of March 1, 2026, positioning the company well to fund growth and the share repurchase program [6][7][8] - The company is targeting revenue between $180 million and $200 million for 2026, with a clear path to adjusted EBITDA profitability by Q4 2027 [5][9][11] Strategic Decisions and Business Focus - Prenetics has completed three strategic divestitures to concentrate on its highest-growth and highest-margin business, IM8, which has been co-founded with David Beckham and is gaining traction in the premium nutrition market [6][11][13] - The share repurchase program is seen as a disciplined choice for capital allocation, allowing the company to return value to shareholders while maintaining sufficient capital for growth [8][10] Market Position and Growth Potential - IM8 has quickly become one of the fastest-growing brands in consumer health, surpassing $100 million in annualized recurring revenue within 11 months of operations and is now sold in over 30 countries [13][14] - The company's enterprise value is approximately $89 million, which is less than 0.5 times IM8's projected revenue for 2026, suggesting that the market is undervaluing the business [5][10]

Hims & Hers Health, Inc. (NYSE:HIMS) is among the 10 Fastest Growing NYSE Stocks to Buy. Barclays Lowers its Price Target on Hims & Hers Health, Inc. (HIMS) to $25 and Keeps an Overweight Rating On February 24, 2026, Barclays lowered its price target on Hims & Hers Health, Inc. (NYSE:HIMS) to $25 from $48 and kept an Overweight rating on the shares. That same day, TD Cowen analyst Jonna Kim lowered the firm’s price target to $17 from $20 and maintained a Hold rating, citing near-term pressure until there ...

Core Insights - Fast-growing stocks are attracting investor attention due to strong earnings momentum, particularly in technology sectors, as highlighted by Vanguard's 2026 Economic and Market Outlook [2][3] - The ability to sustain revenue expansion supported by structural trends is crucial for differentiating high-growth companies in the current market environment [3][5] - J.P. Morgan Asset Management emphasizes that profit growth has been impressive, with four consecutive quarters of double-digit earnings growth, favoring companies benefiting from long-term structural drivers [4][5] Company Summaries - **Brookfield Asset Management Ltd. (NYSE:BAM)**: Reported Q4 EPS of 47 cents, exceeding the consensus estimate of 44 cents. Fee-bearing capital grew to $603 billion, a 12% year-over-year increase, driven by record quarterly fundraising of $35 billion. The company announced a 15% increase in its quarterly dividend to 50.25 cents per share [10][11][12] - **Hims & Hers Health, Inc. (NYSE:HIMS)**: Reported Q4 EPS of 8 cents, below the consensus estimate of 19 cents. Q4 revenue was $617.82 million, slightly above the consensus of $617.25 million. The company has over 2.5 million subscribers and is expanding its services, including hormone therapies and diagnostics [13][15][16]

CORPORATE OVERVIEW Bayer AG March 2026 Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. 2 /// Bayer AG /// Corporate Overview /// March 2026 Global Leader in Health & Nutrition: Uniquely Positioned to Meet Basic Needs of Humankind Crop Science Pharmaceuticals Various known and unknown risks, uncertainties and other factors could lead to material differences between the act ...

Core Insights - Perrigo Company plc, a leading global provider of consumer products, will present at the UBS Global Consumer and Retail Conference on March 11, 2026 [1] - The company specializes in over-the-counter (OTC) self-care products, providing accessible health and wellness solutions primarily in North America and Europe [1] - Perrigo's business model focuses on leveraging cash-generative store brand private label offerings to invest in leading brands such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula® [1] Company Overview - Perrigo is recognized as a pure-play consumer health company with over a century of experience in delivering high-quality health solutions [1] - The company emphasizes the importance of accessibility and choice for consumers through its diverse product offerings across various molecules, dosage forms, and value tiers [1] Event Details - The presentation by President and CEO Patrick Lockwood-Taylor will be accessible via webcast on the Perrigo website [1]

Core Insights - Prenetics Global Limited has announced that its executive leadership team has made significant personal investments in the company's stock, totaling approximately $2.75 million across two consecutive post-earnings trading windows [1][2][5]. Group 1: Executive Investments - CEO Danny Yeung invested approximately $750,000 in this round, increasing from his previous investment of about $502,000 in November 2025 [1][3]. - The executive team collectively acquired 76,060 shares for an aggregate purchase price of approximately $1,301,000, at an average price of approximately $17.11 per share [2]. - Other executives also participated in the investment, with CFO Stephen Lo purchasing 15,603 shares for approximately $250,000, CMO Rahul Ramchand acquiring 15,000 shares for approximately $251,000, and President of Americas David Vanderveen buying 3,175 shares for approximately $50,000 [3][4]. Group 2: Company Performance and Outlook - The IM8 business, a premium health and longevity brand under Prenetics, is reportedly performing well, with the leadership team expressing confidence that the current share price does not reflect the company's progress [5]. - IM8 has achieved over $100 million in annualized recurring revenue within just 11 months of operations and is now available in more than 30 countries [5].

We recently published 10 Stocks Left Behind in a Roaring Market. Haleon plc (NYSE:HLN) was one of the worst performers on Wednesday. Haleon dropped its share prices by as much as 7.67 percent on Wednesday to close at $10.43 apiece after missing its revenue growth guidance last year. In an updated report, Haleon plc (NYSE:HLN) said that it incurred an organic revenue growth of 3 percent, missing its previous outlook of 3.5 percent, primarily dampened by a weakening US consumer environment, coupled with a ...

Financial Data and Key Metrics Changes - The company reported organic sales growth of 3% for 2025, which was below expectations due to a slowdown in the U.S. market and a weaker cold and flu season [8][9] - Gross margin improved by 220 basis points, contributing to a high single-digit operating growth at constant currency [10][44] - The company anticipates organic sales growth guidance of 3%-5% for 2026, indicating a potential sequential acceleration [6][11] Business Line Data and Key Metrics Changes - The U.S. market experienced a decline of approximately 0.5%, while APAC, EMEA, and LATAM grew in the mid-single digits [8][9] - Oral health business showed strong performance, helping to offset declines in the cold and flu category [9][20] - The company plans to focus on driving category growth through investments in advertising and promotion (A&P) and innovation [10][12] Market Data and Key Metrics Changes - Emerging markets, particularly India and China, are expected to contribute significantly to growth, with India showing double-digit growth and strong performance in oral health [29][30] - The company noted a slowdown in LATAM, particularly in Q4, due to challenging macroeconomic conditions [30][31] - E-commerce is growing aggressively in China, with significant contributions from platforms like Douyin [29][30] Company Strategy and Development Direction - The company has restructured its leadership to enhance agility and drive growth, including the creation of a Chief Growth Officer role and six operating units [15][18] - Focus on innovation and commercial execution is emphasized to improve competitiveness in the U.S. market [15][19] - The company aims to leverage its strengths in oral health and expand its reach in emerging markets [12][29] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the uncertain market conditions but expressed confidence in returning to the medium-term growth target of 4%-6% [11][68] - The company is focused on addressing consumer needs and driving category growth despite current challenges [52][53] - Management highlighted the importance of the cold and flu category for overall consumer health and its role in securing shelf space [56][57] Other Important Information - The company has increased A&P investment by over 7% compared to the previous year, with a significant portion allocated to oral health and emerging markets [35][75] - The productivity program has been successful, allowing for flexibility in investments for growth [44][46] Q&A Session Summary Question: What are the main drivers behind the organic sales growth guidance of 3%-5% for 2026? - Management indicated that the guidance reflects expected market improvements and a focus on driving category growth through investments and innovation [6][11] Question: Can you discuss the new reorganization and its impact on growth in the U.S.? - The reorganization aims to unlock growth and agility, with a focus on commercial execution and category strategies [15][18] Question: How is the performance in emerging markets, and what are the growth drivers? - Emerging markets are performing well, particularly in India and China, with a focus on volume growth and expanding reach [29][30] Question: How does the company plan to balance top-line performance with margin improvement? - Management emphasized the importance of investing in the right areas to drive sustainable growth while improving margins [35][36] Question: What is the outlook for the cold and flu business and its importance? - The cold and flu category is crucial for consumer health and shelf space, with management confident in its long-term growth potential [56][57]